Skip to content
Maui Sky – Lifestyle
Author:
Recursion Pharmaceuticals
Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair
November 2, 2026
Recursion Appoints Fred Hassan as Chair of the Board
November 2, 2026
Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3
October 26, 2026
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
October 15, 2026
Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock
October 15, 2026
Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
August 5, 2026
Recursion to Participate in Upcoming Investor Conferences
August 4, 2026
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
July 31, 2026
Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th
July 29, 2026
Recursion to Participate in Upcoming Investor Conferences
June 2, 2026
1
2
Next Page
→